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36Conventional pretransfusion testing based on hemagglutination assays can be chal-
lenging for patients with autoimmune hemolytic anemia (AIHA) because of the pres-
ence of auto-antibodies. It has been suggested that deoxyribonucleic acid-based
methods could be more efficient in the selection of antigen-matched red blood
cell units in those settings. Because of the high risk of alloimmunization of these pa-
tients and the labor-intensive nature of adsorption techniques, we decided to eval-
uate the feasibility of selecting antigen-matched units on the basis of RBC
genotyping. We included in our routine RBC genotyping program samples from 7 pa-
tients with AIHA presenting a strongly positive direct antiglobulin test. This made the
routine compatibility tests difficult. Most patients hadpreviously received transfusions
because of warm AIHA. Matched donor units were selected according to the geno-
type. For all but 1 patient, blood group genotyping could be done on time to allow
antigen-matched transfusion. Four patients received antigen-matched red blood
cell units based on RBC genotyping and for 1 patient the fact that no matched units
were available led us to postpone the transfusion. After each transfusion, the recov-
ery was recorded and considered satisfactory for all transfused patients. (Transla-
tional Research 2014;163:36–42)Abbreviations: AIHA ¼ autoimmune hemolytic anemia; RBCs ¼ red blood cells; DAT ¼ direct
antiglobulin test; DNA ¼ deoxyribonucleic acid; EDTA ¼ ethylenediaminetetraacetic acid;
G6PD ¼ glucose-6-phosphate dehydrogenase; INR ¼ International normalized ratio; LISS-IAT
¼ low ionic strength solution-indirect antiglobulinA utoimmune hemolytic anemia (AIHA) is anuncommon disease characterized by anincreased destruction of red blood cells
(RBCs) mediated by autoantibodies directed against au-
tologous RBCs. AIHA can be classified into different
types including warm AIHA, cold agglutinin syndrome,
paroxysmal cold hemoglobinuria, mixed-type AIHA,
and drug-induced immune hemolytic anemia.sfusion, Hospital Blood Bank,
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from the Brugmann Foundation.Some patients with AIHA may require blood
transfusion, according to the severity of anemia and their
clinical status. It is generally thought that when the in-
compatibility is due to the presence of an autoantibody
alone, the survival of transfused RBCs is similar to
that of a patient’s RBCs. However, classical pretransfu-
sion hemagglutination assays are often difficult to inter-
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Background
Patients with autoimmune hemolytic anemia
(AIHA) are at high risk to develop a hemolytic
transfusion reaction due to an alloantibody. The
rate of alloimmunization in these patients is often
higher than in other multitransfused patients and,
because of autoantibodies, traditional compatibil-
ity tests can be challenging or impossible. We,
thus, started to determine blood group genotype
of patients with AIHA and we report its application
and feasibility.
Translational Significance
In our experience, RBC genotyping techniques for
patients with AIHA allow selecting antigen-
matched units without laborious, costly, lengthy,
and sample consuming adsorption procedures.
This application is particularly useful for pediatric
patients with small blood samples.
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to exclude these autoantibodies because they can also
mask the detection of alloantibodies that can lead to
a harmful immuno-hemolytic reaction.
Additionally, the rate of alloimmunization is higher in
patients with warm AIHA than in other multitransfused
patients.1 In fact, several studies report that 12% to
40% of patients with warm AIHA have significant
alloantibodies.2-8 The risk of underlying alloantibodies
has prompted transfusion laboratories to provide
specialized compatibility testing procedures that allow
for the detection of alloantibodies in patients with
masking autoantibodies. A variety of methods have
been described for the selection of RBCs for patients
with autoantibodies. Selecting RBCs for transfusion by
providing ‘‘least incompatible units’’ or by testing
a patient’s diluted serum against a panel of RBCs to
detect a more strongly reacting alloantibody are deemed
to be unacceptable procedures.1 For patients with warm
AIHA, themost effective compatibility testing rely on au-
toadsorption techniques that consist in incubating pa-
tient’s RBCs at 37C with his or her own serum to
remove the autoantibody and to allow detection of clini-
cally significant alloantibodies. In this technique, some
of the antibody is also eluted from the patient RBCs
thanks to a treatment with proteolytic enzyme. A less
labor-intensive alternative involves an autoadsorption us-
ing polyethylene glycol,which negates the need for an ad-ditional enzymatic step.1,9,10 This technique, although
less labor-intensive, might, however, not be feasible in
patients with severe anemia, as the large volume of autol-
ogous blood required for autoadsorption procedure is not
always available. Moreover, if the patient has already
received transfusions in the past, the validity of an autoad-
sorption is questionable because of the mixture of the
patient and donor RBCs.11 The most suitable procedure
will then consist in adsorption using allogeneic RBCs of
different known phenotypes that allows removing the
autoantibody from the patient’s serum.
In general, adsorption procedures are heavy,
lengthy, and sample-consuming. A strong collabora-
tion between the clinician and the blood bank staff
is, therefore, essential to evaluate the need and the ur-
gency of the transfusion and to guide the selection of
appropriate compatibility test procedures in a way
that will provide RBC units as safely and timely as
possible.
Depending on the urgency of the transfusion need, the
results may not be available prior to the transfusion of
the first RBC unit but remain useful for further transfu-
sions. For these reasons, the determination of the most
complete phenotype (including RH1, RH2, RH3,
RH4, RH5, KEL1, FY1, FY2, JK1, JK2, MNS1,
MNS2, MNS3, and MNS4 antigens) coupled with the
delivery of prophylactic antigen-matched donor blood
has been proposed as an alternative method to the ad-
sorption techniques12 for patients with warm AIHA.
This approach is only applicable when the patient
does not have a strongly positive direct antiglobulin
test (DAT) or has not been transfused.12 In cases of pa-
tients with recent transfusions or strongly positive
DATs, there are no effective serologic alternatives to ad-
sorption procedures.
Although hemagglutination remains the gold stan-
dard method in immunohematology reference laborato-
ries, molecular immunohematology is increasingly used
as a valuable method to provide appropriate transfusion
support, to reduce the risk of transfusion reactions,
and to prevent alloimmunization in multitransfused
patients such as those with sickle cell disease patients
or thalassemia.13,14 Blood group genotyping is
also used to detect variants when hemagglutination
tests show a weak or altered antigen expression,
especially in a context of pregnancy or previous
transfusion.15,16
Therefore, we have considered the option to
apply blood group genotyping using a high-
throughput deoxyribonucleic acid (DNA) assay rather
than extended RBC phenotyping to manage the trans-
fusion support of patients with AIHAwho have a high
risk of alloimmunization and are likely to be multi-
transfused.
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Patient selection. The study protocol was carried out
according to the principles of the Declaration of Hel-
sinki. During a period of 1 year, samples from patients
with AIHA (n 5 7) were included in the routine blood
group genotyping program. This program was adapted
to include EDTA blood samples collected from patients
with warm autoantibodies as quickly as possible based
on the availability of qualified laboratory staff and on
the time of sample receipt. For 1 patient out of 7, it
was not possible to wait for the genotyping before trans-
fusion of the first blood unit, and this was due to poorly
supported anemia. When the sample had a strongly pos-
itive DAT with anti-IgG and a panagglutinin in the
plasma making antibody screens and cross-matching
difficult, genomic DNA was extracted from an aliquot
of 200 mL EDTA whole blood sample using the
QIAamp DNA Blood Minikit (Qiagen). The DNA
sample was included in the routine batch of samples
waiting for genotyping.
Genotyping method. Molecular analyses were per-
formed using the BioArray HEA BeadChip (Immucor,
Warren, NJ). Polymerase chain reaction amplification
was performed in a Veriti thermal cycler (Applied Bio-
systems) with a set of primers selected by the manufac-
turer to generate the amplicons with the polymorphic
sites of interest. After an elongation step, polymerase
chain reaction products were incubated on BeadChip
(Immucor) carriers. The fluorescence pattern was ac-
quired and analyzed by the proprietary BASIS software
to generate phenotype and genotype reports.
Donor units matched to the patient’s phenotype were
selected according to RH1, RH2, RH3, RH4, RH5,
KEL1, FY1, FY2, JK1, JK2, MNS1, MNS2, MNS3,
and MNS4 antigens. However, the routinely used Bead-
Chip (Immucor) allows determination of minor poly-
morphisms, in addition to these major group systems.
When necessary, 2 other panels are available for variants
for the Rh blood group system. This approach allows re-
liable genotyping of almost all patients except very rare
unknown variants requiring gene sequencing.15
All routine tests, such as low-ionic-strength solution-
indirect antiglobulin (LISS-IAT) screen and antibody
identification panel, were performed by hemagglutina-
tion gel test according to the manufacturer instructions
(BioRad). DAT was performed with the gel test using
polyspecific anti-IgG and anti-C3 reagents and the elu-
ate with a commercial test kit (BioRad).RESULTS
We present here a description of 7 patients with AIHA
for whom we have introduced blood group genotyping
in our transfusion management strategy.Patient no. 1. The first patient was a 70-year-old
woman who developed warm AIHA secondary to
chronic lymphocytic leukemia and had previously
required transfusion of 13 RBCs units in 7 episodes.
She was admitted to our emergency department with
dyspnea and pyrexia. Hemoglobin (Hb) concentration
was 6.6 g/dL. The DAT was strongly positive with
autoantibodies that impeded all routine compatibility
tests including the complete phenotype. The LISS-IAT
was positive with a 3 1 reactivity. Six hours later, she
was transfused with 2 selected RBC units matched to
her phenotype that is RH:1,2,-3,4,5; KEL:-1,2; JK:1,2;
FY:-1,2; MNS:1,-2,3,4.
The first transfusion episode was followed by 6 addi-
tional episodes (see Table I). As for the first transfusion
episode, the DAT and LISS-IAT remained positive with
a 2 1 to 3 1 reactivity. All donor RBC units adminis-
tered were matched to her genotype avoiding any addi-
tional auto- or alloadsorption procedures before
transfusion. The latter were, however, programed after
the first, the third, and the sixth transfusion episode
and revealed no new alloantibody. No transfusion reac-
tion was reported, and the RBC recovery was evaluated
after each transfusion.
Patient no. 2. The second patient, an 8-year-old girl,
was admitted to the emergency department for an
AIHA in the context of Aicardi-Goutieres syndrome
with an Hb concentration of 7.2 g/dL. Three years
ago, she had an episode of AIHA that required
transfusion of 2 RBC units. Because of the patient
pathology and her transfusion history, she was
considered at risk for further transfusions.
All routine compatibility tests, including the com-
plete serologic phenotype, were confusing due to
a strongly positive DAT with anti-IgG and anti-C3d
and the presence in her plasma of a pan-agglutinin.
We performed RBC genotyping that helped us to
preselect an antigen-matched RBC unit ordered to our
Blood Transfusion Service. This antigen-matched unit
(RH:1,2,-3,-4,5; KEL:-1,2; JK:1,2; FY:-1,2; MNS:1,-
2,-3,4) was transfused during her stay when her Hb
fell to 4.9 g/dL. Post-transfusion Hb concentration
reached 9.4 g/dL (see Table I) without any transfusion
reaction. The adsorption procedure performed 1 week
after the transfusion did not reveal the presence of any
alloantibody.
Patient no. 3. The third patient, an 83-year-old woman,
was admitted to our emergency department with chest
pain for 4 days and pain in her right hypochondrium.
She was under anticoagulant treatment since a previous
episode of venous thromboembolism. International
normalized ratio increased at admission revealed an
overdose in acenocoumarol. She was pale and icteric,
and her Hb concentration was 7.7 g/dL, haptoglobin










at least 1 week
post-transfusion
Patient no.1
1 2 RH:-3; KEL:-1; FY:-1; MNS:-2 5.1 7.7 None
2 2 RH:-3; KEL:-1; FY:-1; MNS:-2 4.8 7.8
3 2 RH:-3; KEL:-1; FY:-1; MNS:-2 6.8 8.8 None
4 2 RH:-3; KEL:-1; FY:-1; MNS:-2 5.2 7.3
5 1 RH:-3; KEL:-1; FY:-1; MNS:-2 5.4 6.5
6 2 RH:-3; KEL:-1; FY:-1; MNS:-2 6.9 10.1 None
7 2 RH:-3; KEL:-1; FY:-1; MNS:-2 5.8 7.2
Patient no. 2
1 1 RH:-3;-4; KEL:-1; FY:-1; MNS:-2,-3 4.9 9.4 None
Patient no. 3
1 1 RH:-2,-5; JK:-1; FY:-2; MNS:-2 6.9 7.6 None
2 2 RH:-2,-5; JK:-1; FY:-2; MNS:-2 7.1 5.8*
3 9 Transfusion of not matched units 4.9† 8.1
4 4 RH:-2,-5; JK:-1; FY:-2; MNS:-2 7.3 12.2 None
Patient no. 4
1 1 Transfusion of not matched unit 6 9.3
2 1 RH:-3,-4; KEL:-1; MNS:-3 3.1 8.0
3 1 RH:-3,-4; KEL:-1; MNS:-3 4.9 7.7
Abbreviations: Hb, hemoglobin; RBC, red blood cell.
*Hb concentrations remaining low because of gastrointestinal bleeding.
†Hb concentrations during the episode of acute gastrointestinal bleeding.
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IgG auto-antibodies that precluded all routine
compatibility tests including the complete phenotype.
The LISS-IATwas positive with 31 reactivity.
The decision to postpone transfusion was made by the
emergency physician, and the patient was transferred to
the hematology department. The following RBC
genotype was identified: RH:1,-2,3,4,-5; KEL:1,2;
JK:-1,2; FY:1,-2; MNS:1,-2,3,4. Because of heart fail-
ure, the hematologist prescribes the transfusion of
1 matched RBC unit (see Table I). During her stay,
her Hb concentration continued to decline, the
esophago-gastroduodenoscopy revealed the presence
of duodenal ulcers causing a gastrointestinal bleeding,
and two additional RBC units matched were transfused.
Two days later, she was transferred to the intensive care
unit for an acute gastrointestinal bleeding requiring the
massive transfusion of 9 RBCs units, 8 fresh frozen
plasmas, and 2 platelet concentrates. However, during
this acute transfusion episode, we could not match
with her complete phenotype for the units administered.
After being stabilized, 4 other RBC units were finally
transfused with correctly matched units in another trans-
fusion episode. Adsorption procedures were performed
before the first and after the last transfusion episode, and
no alloantibodies could be been detected.
Patient no. 4. An almost 3-year-old girl was admitted
to the emergency department for severe S. pneumoniae
infection, associated with acute renal failure,thrombocytopenia, and AIHA. We found a strongly
positive DAT with anti-IgG and anti-C3d and the
presence in her plasma of a pan-agglutinin impeding
our routine compatibility tests. She had no history
of previous transfusion. At admission, her Hb
concentration was 6.0 g/dL. She was transferred to the
intensive care unit where she received a first
nonmatched RBC unit. Because of the high risk of
further transfusions and the impossibility to conduct
any adsorption studies because of the lack of
sufficient serum samples, we decided with the
physician to perform a RBC genotyping.
During her hospitalization, 2 additional preselected
antigen-matched blood units RH:1,2,-3,-4,5; KEL:-1,2;
JK:1,2; FY:1,2; MNS:1,2,-3,4 were administered (see
Table I).
Patient no. 5. An 80-year-old man developed AIHA
secondary to myelodysplastic syndrome and had
a history of transfusion episodes. During this
period, DAT was strongly positive with anti-IgG and
anti-C3d, and the autoantibodies impeded all routine
compatibility tests including the complete
phenotype. The LISS-IAT was positive with 21/
3 1 reactivity.
Adsorption studies of his samples were performed
prior to each transfusion. A significant alloantibody
known to cause serious hemolytic transfusion reactions
(anti-Jka) was discovered after 1 of these adsorption
procedures. During the last hemolytic episode, four
Translational Research
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procedure was laborious and was not available before
the transfusion of the first unit.
This patient was regularly followed up in the
hemato-oncology clinic and was included in the RBC
genotyping protocol. Genotyping revealed a common
Caucasian RBC phenotype, which was easily found
in our donor population. In case of the for additional
RBC, further units will be immediately selected ac-
cording to his genotype without performing any other
adsorption procedure.
Patient no. 6. The sixth patient, a 38-year-old man,
presented 1 year before with a primary AIHA for
which he had required an emergency transfusion of 2
RBC units. He was regularly followed at the
outpatient hematology clinic. He had a consistent
strongly positive DAT with anti-IgG, a 2 1 reactivity
positive LISS-IAT and an Hb level at the lowest limit
of normal range. This patient remained at risk for
a new hemolytic episode as in most patients with
primary AIHA.17 Given this context, we conducted
genotyping of blood groups to subsequently allow fast
selection of most suitable units of RBC.
Patient no. 7. An 11-year-old African boy was pre-
sented with a complex hemolytic anemia caused by
both a known G6PD deficiency and a recurrent primary
AIHA. He was admitted to the emergency department
for abdominal pain. At the admission, he had an Hb con-
centration of 5.2 g/dL, haptoglobin,3mg/dL, a strongly
positive DAT with anti-IgG, and anti-C3d and
a panagglutinin impeding our routine compatibility
tests. His important transfusion history (10 RBCs
transfused in the past) led us to immediately start
autoadsorption procedure, which failed because we
could not get enough blood for all tests.
We, therefore, decided to perform a blood group
genotyping before any further transfusion. His geno-
type was determined as RH:1,-2,-3,4,5; KEL:-1,2;
JK:1,-2; FY:-1,-2; MNS:-1,2,-3,4. Matched blood
was not immediately available due to this rare pheno-
type in our population of mostly Caucasian blood do-
nor. We, therefore, postponed the transfusion, in
agreement with the pediatrician, since the patient was
clinically stable. Corticosteroids started at day 0 in-
duced a rapid increase in hemoglobin (3 g/dL in
10 days). Autoadsorption procedures were carried out
as soon as his hemoglobin was high enough to collect
the sample of blood required, and it revealed the pres-
ence of an anti-RH5. The molecular analysis of the
most frequent mutations responsible for RH5 variants
ruled out the presence of a partial RH5 antigen that
would induce an alloimmunization. We, thus, consid-
ered the anti-RH5 as an autoantibody.DISCUSSION
PatientswithAIHA are at high risk to develop a hemo-
lytic transfusion reaction because of an alloantibody.
The rate of alloimmunization in these patients is even
higher than in other multitransfused patients such as
thosewith sickle cell disease or thalassemia.1Moreover,
traditional compatibility tests can be challenging or im-
possible because of the presence of autoantibodies.
For these reasons, as recently recommended,14 we
started to genotype patients with AIHA to determine
their blood group antigens, and we here report its appli-
cation and feasibility for 7 patients. For every patient
before each transfusion, the physician was informed
of the genotyping procedure for compatibility testing,
and he was asked to keep us informed of post-
transfusion recovery.
For some patients, genotyping allowed us to avoid
systematic labor-intensive autoadsorption procedures
for the following episodes of transfusion.
Four patients presenting with AIHA had a hemato-
oncologic pathology.
- For the first patient, who had an important history of
transfusions, this transfusion strategy was very ben-
eficial. Indeed, the matched units selected in this
way were transfused in at least 6 other transfusion
episodes with satisfactory post-transfusion recovery.
- The history of patient no. 5 revealed a large number
of previous transfusions that had required the appli-
cation of multiple laborious autoadsorption proce-
dures, allowing to discover an allo- anti-Jka. RBC
genotyping for this patient was an option to facilitate
faster and easier selection of compatible units of
blood, thanks to the wide availability of units of its
phenotype.
- Patient no. 6 presented with primary AIHA and had
previously received 2 blood units. He still had
a strongly positive DAT (IgG type) even without ad-
ditional hemolytic episodes. The decision to perform
the genotyping as a preventive measure was made
with his primary physician.
- For patient no.7 who presented with an Hb concen-
tration of 5.2 g/dL, we could infer the blood group
phenotype despite the small amount of sample. Be-
cause of the unavailability of this phenotype in our
blood bank, we decided to postpone the transfusion.
Contrary to a widespread assumption, it is important
to note that hemato-oncologic patients have a similar
risk of alloimmunization as other multitransfused pa-
tients.17 In addition, increased incidence of AIHA for
these patients could be related to the more widespread
usage of purine analogs.18Most of these patients receive
multiple transfusions, either planned or in an emergency
Translational Research
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senting with a strongly positive DAT with anti-IgG
and panagglutinin in the plasma, RBC genotyping en-
ables antigen-matched unit selection as soon as the
need for a transfusion is known.
In pediatrics, RBC genotyping offers an additional
advantage over the auto-adsorptions because of difficul-
ties in collecting sufficient blood volume for adsorption
studies.
Indeed, for 2 of the 3 pediatric patients, we could per-
form genotyping before deciding on the transfusion.
This was important given that these patients had been
transfused in the past and because of the unavailability
of samples for autoadsorptions. For the child who has
been transfused without matched RBCs and without au-
toadsorption testing, we took into account the fact that
he had not been previously transfused. For the following
transfusions of this patient, the blood group genotype
was then available, and we transfused only matched
RBCs.
In the study of Shirey et al12 who realized an extended
typing of patients with AIHA, the typing could not be
achieved (not possible) in 40% of the cases and autoad-
sorption tests have been performed to find a potential al-
loantibody. In contrast to genotyping, extended typing
with serology often cannot be conducted for all patients
because of the limited availability of certain antisera
and prior transfusion history. Although RBC genotyp-
ing cannot be performed in all immunohematology lab-
oratories, as it is the case for adsorption techniques,
these analyses can be accommodated by reference lab-
oratories, which have a sufficiently high genotyping ac-
tivity to treat emergency samples without delay.
This procedure requires a strong understanding by the
physician of the issues related to red blood cell compat-
ibility testing and of the benefits of RBC genotyping for
these patients. Applying such a procedure allows to de-
crease alloimmunizations and to lower the risk of trans-
fusion reactions. In addition, RBC genotyping has the
potential to decrease the workload and cost associated
with complex serologic compatibility testing, especially
in patients who are multitransfused.
It is also to be noted that all but 1 patient tested in this
study presented Caucasian RBC phenotypes, which led
to an easier selection of antigen-matched units. This
procedure could become more difficult if we have to
match genotype between patients and donors with dis-
similar ethnicities. In our institution, most of blood do-
nors are Caucasian and that can lead to difficulties to
find matched blood for some patients as illustrated by
patient no. 7. For these recipients, we need to maintain
our adsorption procedures; however, even in these
cases, genotyping enables the selection of fewer panel
cells for alloadsorption.For patients with AIHA, testing for the detection of
alloantibodies takes a minimum of 4 to 6 hours, needs
large samples, and may not be contributive.
Therefore, RBC genotyping, if available, must be pro-
posed and discussed with the physician who will bal-
ance the risk of waiting several hours for matched
RBC units with the risk of hemolytic reactions.
In conclusion, RBC genotyping techniques for pa-
tients with AIHA allow selecting antigen-matched units
without heavy, costly, lengthy, and sample consuming
adsorption procedures. This application is particularly
useful for pediatric patients with small blood samples.
However, adsorption methods may still be needed
when the patient’s genotype does not allow antigen-
matched units selection. In case of former transfusions,
the patient’s genotype is still useful for selecting panel
cells used in the alloadsorption. Communication be-
tween blood bank staff and the hematologist in charge
of the patient is essential, a key success factor in the im-
plementation of this procedure.
Although a small number of samples have been
tested, we have found that RBC genotyping is highly
beneficial for patients with AIHA and makes the selec-
tion of compatible blood considerably easier, even in an
emergency context. A larger study should, however, be
conducted to confirm that genotyping is more efficient
than the current serologic procedure to reduce the risk
of alloimmunization, delayed hemolytic transfusion re-
action, and decreased RBC survival because of an unde-
tected alloantibody.REFERENCES
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